Australia markets open in 1 hour 23 minutes

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.20+0.04 (+0.49%)
At close: 04:00PM EST
8.20 0.00 (0.00%)
After hours: 04:04PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.16
Open8.16
Bid8.16 x 800
Ask9.51 x 800
Day's range8.16 - 8.31
52-week range7.57 - 24.26
Volume314,866
Avg. volume540,972
Market cap374.456M
Beta (5Y monthly)1.02
PE ratio (TTM)N/A
EPS (TTM)-1.43
Earnings date27 Feb 2023 - 03 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est26.17
  • Zacks

    Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?

    The mean of analysts' price targets for PMV Pharmaceuticals, Inc. (PMVP) points to a 267.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • GlobeNewswire

    PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

    CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will al

  • GlobeNewswire

    PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

    Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA® (pembrolizumab) on track to initiate in 2022 Biotech industry veteran Dr. Carol Gallagher appointed to Board of Directors CRANBURY, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology com